stock markets for traders. period
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
http://www.kinross.com/class-action-lawsuit/kinross-responds-to-southridge-news-release.aspx
curious why this has been posted under class-action-lawsuit folder...
those clowns have no choice to stay on NASDAQ with no r/s... nice step forward, Andi... idiots...
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8969261
At this meeting you will be asked to consider the following proposals:
1. To elect the seven director nominees named in the Proxy Statement to hold office until the next annual meeting of stockholders;
2. To ratify the appointment of CohnReznick LLP as the Company’s independent auditors for the fiscal year ending April 30, 2013;
3. To approve an amendment to the Certificate of Incorporation of the Company to effect a reverse stock split of the Company’s common stock, at a ratio of not less than one-for-two and not greater than one-for-ten, with the exact ratio to be set within such range in the discretion of the Board of Directors without further approval or authorization of the Company’s shareholders, provided that the Board of Directors determines to effect the reverse stock split and such amendment is filed with the Secretary of State of Delaware no later than one year from the date of the Annual Meeting. The purpose of this proposal is to enable the Company to regain compliance with the minimum per share bid price requirement so that we may continue our listing on The NASDAQ Capital Market;
4. To approve an amendment to the Certificate of Incorporation of the Company to increase the Company’s authorized shares of common stock from 25,000,000 to 100,000,000;
5. To approve the potential issuance of more than 20% of the Company’s issued and outstanding common stock at a price that is less than the greater of book or market value in accordance with a securities purchase agreement between the Company and the Buyers named therein, dated December 4, 2012 (the “Private Placement”); and
6. To act on such other matters as may properly come before the meeting or any adjournment there.
good volume & share price appreciation 2day...
WPCS Secures Private Placement Financing
EXTON, PA--(Marketwire - Dec 5, 2012) - WPCS International Incorporated (NASDAQ: WPCS), a leader in design-build engineering services for communications infrastructure, has announced that it has entered into a private placement with six accredited investors for the sale of $4 million of senior secured convertible notes (the "Notes") and warrants (the "Warrants") to purchase shares of WPCS' common stock. The closing of this transaction is conditioned upon satisfaction of closing conditions, which have all been satisfied except receipt of the funds, which should be completed today.
Under the general terms of the Notes, WPCS will be able to draw down daily against the $4 million of gross proceeds based on available cash in a lockbox account plus 95% of available qualified accounts receivables, less a reserve of $250,000 and less the total amount of principal, accrued interest, fees, costs and expenses owed pursuant to the Notes. At closing, it is anticipated that WPCS will initially draw down approximately $2.2 million to retire the existing $2 million senior revolving line of credit with Sovereign Bank, N.A., and related fees and expenses. The Notes are convertible into shares of common stock at an initial conversion price of $0.3768 per share.
The investors will also receive warrants to purchase an aggregate of 15,923,567 shares, exercisable for five years at an initial exercise price of $0.471 per share. The conversion and exercise prices of the Notes and Warrants will be adjusted to 85% of market price on the occurrence of certain future adjustment dates as defined in the transaction documents. The Notes will mature on the eighteen-month anniversary of the closing date and will bear interest at the rate of 4% per annum, payable quarterly in arrears. The definitive agreements containing the details of the financing will be filed as exhibits to a Current Report on Form 8-K, that will be filed with the Securities and Exchange Commission.
Joseph Heater, Chief Financial Officer of WPCS, commented, "We are pleased to announce the successful completion of the financing. The Notes provide adequate financing to repay Sovereign Bank and gives us the ability to obtain additional working capital through the available qualified accounts receivable parameters and from any future conversion of Notes to common shares. We believe we are completing a turnaround in operating performance while securing the working capital needed to deliver better operating results in the future."
likely...
congrats buddy > $7.20 so far... should be up more next week...
added $TZYM... oversold like ...
Sunshine Heart Receives Unconditional FDA Approval for C-Pulse(R) System's U.S. Pivotal Trial
EDEN PRAIRIE, MN and SYDNEY, AUSTRALIA--(Marketwire - Nov 20, 2012) - Sunshine Heart, Inc. ( NASDAQ : SSH ) ( ASX : SHC ), a global medical device company focused on innovative technologies for moderate to severe heart failure, today announced it has received unconditional approval from the FDA to commence its pivotal U.S. trial for its flagship C-Pulse® Heart Assist System.
"We are pleased to have expeditiously completed the approval process with the FDA. We are excited to evaluate the C-Pulse System's potential in treating patients suffering from Class III and ambulatory Class IV heart failure. We also are eager to evaluate its clinical and economic impact in reducing re-hospitalization rates due to worsening heart failure as this represents the highest and most costly re-hospitalization rates plaguing the U.S. healthcare system today. All of us at Sunshine Heart are committed to expediting this next phase of technology advancement," commented Dave Rosa.
Sunshine Heart plans to initiate the pivotal trial in North America in the fourth quarter of 2012. The Company has contacted a number of leading heart failure centers in the U.S. and to date is encouraged by the positive response to participate in the trial. The trial design will consist of 388-patients of which half will be implanted with the C-Pulse System. The other half will be randomized to optimal medical therapy across 30-40 clinical sites. Sunshine Heart expects to receive revenues from trial sites for device implants as the FDA has granted CMS Category B3 status. Because of this designation, it is also anticipated that participating trial centers will be reimbursed by CMS and most private insurance providers. The trial will utilize the Company's next-generation single unit C-Pulse driver, which received approval for clinical trial use from the FDA in August, 2012, and has been in use in Canadian and U.S. patients currently on the device. The new driver features a single unit, which is lighter, quieter, approximately half the size of its predecessor, and also includes numerous software updates.
In July, Sunshine Heart announced positive 12-month extended follow-up data from its preliminary feasibility study of the C-Pulse® Heart Assist System. Extended data included positive efficacy trends with continued improvements in NYHA Class reduction, MLWHF Quality of Life score, and six minute hall walk. There were no additional patients with device-related serious adverse events (SAEs) in this 12 month time frame. Also in July, the Company achieved CE Mark certification, allowing commercialization of the device in Europe. The Company has been targeting leading LVAD and transplant centers in the EU. Specific initial focus for the device has been within Germany and Italy, two countries that when combined, are believed to have the highest number of hospital bed days per year for heart failure in Europe.
The Company estimates enrollment for the event-driven pivotal trial will take approximately 2.5 years. The primary endpoint of the trial will be reduction in worsening heart failure events leading to hospitalization, advanced heart failure therapies and heart failure related mortality. A one year safety follow-up is expected. The lead investigator for the trial will be Dr. William T. Abraham, Director of the Division of Cardiovascular Medicine at The Ohio State University Medical Center.
$tsym > shoulda bounce
from TheStreet:
sold $sgyp @ $4.19s from 3.10s ave; buying $tsym by small chunks for the next week...
Going to be a real ATM... They generated $287K from ClearPoint disposable products in Q3 - that's came out only from 15 systems... There are 4500 hospitals with MRI suites in US along... Huge market...
$gtim > small movement... keep watching...
$$$$$$$$
$SGYP > $3.8 HOD weeeeeeeeeeeeeeeeeeeeeeeeee
nicezzz
watching $GTIM 4 a bottom > float is below a mil, wild NASDAQzzzz crapzzz
sgyp > 3.50ssssssssssssssssss !
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8558435
“We are pleased with the growth we realized during the quarter relating to the commercialization of our ClearPoint Neuro Intervention System,” said Kimble Jenkins, CEO of MRI Interventions. “Year-to-date revenues from the sale of ClearPoint disposable products increased 265%, from $269,000 for the nine months ended September 30, 2011 to $713,000 for the same period in 2012. Disposable revenues increased 40% from Q2 to Q3 of this year, with $204,000 in the second quarter increasing to $287,000 in the third quarter. ClearPoint installations continue to grow, as we ended the third quarter with 18 sites, including the addition of luminary hospitals, Ohio State University and Universite Joseph Fourier Hospital in Grenoble, France. Of note, the Grenoble ClearPoint cases represented our first cases in Europe.”
Jenkins continued, “As demand for ClearPoint has increased, we began expanding our ClearPoint sales force during the quarter with the addition of two seasoned neurosurgical sales persons, and subsequent to quarter end, the hiring of Robert Korn as our Vice President, Global Sales and Marketing. In addition, we were pleased to see ClearPoint platform uses continue to grow in the quarter, with multiple sites now using our ClearPoint system to aide in electrode placement, focal laser ablation, direct drug delivery and biopsy procedures.”
“We are pleased to see continued growth in our revenues, with revenues of $3.2 million for the nine months ended September 30, 2012 versus $2.7 million for the same period in 2011. We were also successful in decreasing our operating loss, year-to-date through the third quarter, from $(4.6) million in 2011 to $(2.6) million in 2012. We were able to improve our cash position with an equity financing we closed during the third quarter which resulted in net proceeds of $5.5 million.”
“Overall, we were very pleased with the operating results for the third quarter,” said Jenkins. “We are seeing success in growing our revenues, reducing our operating losses and building a sales and marketing infrastructure which we believe will serve us well in the coming quarters.”
open: $1.63
high: $2.03
close: $1.90 +17.28%
look at historical prices (last run back in July):
2012/07/05 4.00 4.70 3.61 4.45 153,964 4.45
2012/07/04 2.95 3.56 2.95 3.56 115,493 3.56
2012/07/03 2.95 5.00 2.50 3.56 115,493 3.56
2012/07/02 2.35 3.00 2.30 2.51 103,955 2.51
2012/06/29 1.90 3.00 1.80 2.30 98,684 2.30
2012/06/28 1.51 1.85 1.41 1.75 57,550 1.75
not yet. lol
$MRIC > $2 HOD
they hired a big boy from Medtronic (NYSE: $MDT) to push sales UP, UP and awayyyyyyyyyyyyyyyyyyyyyy :)
$SGYP: down too much... should bounce to over $4 this week...
$MRIC: $1.9 x $1.94
very interesting: http://twitter.com/PennyStockHaven/status/268008814358446080
'am buying $SGYP
$MRIC: $1.96 up, going 2 da moooooooooooooooooooon lol
MRI Interventions Appoints Robert C. Korn, Medtronic Veteran, to Head Global Sales and Marketing
MRI Interventions, Inc. (MRIC) announced today that Robert C. Korn has joined the company to head its global sales and marketing efforts. Mr. Korn brings 15 years of medical device sales management experience to MRI Interventions, including an extensive background in neurosurgical and surgical navigation products. Most recently, he served as Regional Sales Director for Medtronic Surgical Technologies, with a focus on growing sales of neurosurgical and navigation products. Prior to Medtronic, Rob was Midwest Division Sales Manager for Codman, the neuroscience division of Johnson & Johnson.
“We are seeing strong growth and increasing market demand for our ClearPoint Neuro Intervention System. Rob’s deep expertise and proven sales leadership in the neurosurgical market will be invaluable to us in directing our expanding sales capabilities as we continue to accelerate our growth,” said Kimble Jenkins, CEO of MRI Interventions.
As Vice President, Global Sales & Marketing, Mr. Korn will spearhead the on-going commercialization efforts for the company’s ClearPoint system. He will be responsible for the continued growth of the company’s highly-focused sales force, which recently added two additional experienced sales representatives, both with significant neurosurgery backgrounds.
“The ClearPoint system represents a long-awaited breakthrough in minimally invasive neurosurgery, impacting a wide range of neurosurgical procedures,” said Mr. Korn. “I am thrilled to have the opportunity to lead the on-going sales and marketing efforts for this important new product platform.”
http://finance.yahoo.com/news/mri-interventions-appoints-robert-c-130000088.html
yeap, got email from exclusivestockalerts... should be more from awesomepennypick...
waited 2month for this crap to be promoted... hoping for .10+
expected... they have enough $$$ 'till mid-2013 but Nexus trials may require much more... offering is imminent...
yes, I did... I'd like to see the Amira's type of development here...
which one?
$1 pre-r/s
put $mtsn on watch too > 3rd Q results today at 5
$gevo > chart lookzzz coolzzz
playin' $gevo
nicezzz
was. lol
curious who was behind of her...